What is the Optimal Fat Mass in Peritoneal Dialysis Patients?

2007 ◽  
Vol 27 (2_suppl) ◽  
pp. 250-254 ◽  
Author(s):  
David W. Johnson

The prevalence of obesity in peritoneal dialysis (PD) populations has risen dramatically since the mid-1980s. This epidemic has been driven by the increased prevalence of obesity in the general population, the increased risk of progression of chronic kidney disease to end-stage renal failure (ESRF) in obese subjects, the reduced probability of listing obese dialysis patients for renal transplantation, a paradoxical enhanced survival in at least some obese populations on dialysis as compared with non-obese ESRF patients, and a possible adipogenic effect of excessive peritoneal glucose absorption in PD. Although obesity has consistently been associated with improved outcomes in hemodialysis, conflicting results have been seen in PD. In general, an elevated body mass index (BMI) has been associated with a neutral or deleterious impact on PD outcomes, and the relationship appears to be explained predominantly by fat mass. Risk is also elevated in patients with a low BMI, such that the “optimal BMI” appears to lie between 20 kg/m2 and 25 kg/m2. The mechanisms underpinning the harmful effect of obesity appear to include increased peritonitis rate, proinflammatory effects, and a more rapid decline of residual renal function in obese patients. No proof exists that weight reduction engenders an improvement in outcome in PD patients, but the available studies suggest that cautious weight reduction is advisable. A few studies have demonstrated that clinically important and sustained weight reduction can be successfully achieved through a combination of individual meal plans, regular exercise, and substitution of icodextrin for dextrose in the once-daily long dwell.

2017 ◽  
Vol 37 (4) ◽  
pp. 477-481 ◽  
Author(s):  
Susie L. Hu ◽  
Priyanka Joshi ◽  
Mark Kaplan ◽  
Judy Lefkovitz ◽  
Andreea Poenariu ◽  
...  

The survival advantage observed among peritoneal dialysis patients early on after dialysis initiation has been largely attributed to residual renal function (RRF) preservation due to higher baseline residual function and fewer comorbidities. We hypothesize that a rapid decline in RRF is associated with higher risk of anuria and mortality. In a retrospective cohort study of 581 subjects on peritoneal dialysis with longitudinal prevalent data, we assessed whether RRF change over time, in addition to baseline RRF, increased risk of mortality and anuria using Kaplan-Meier analysis and Cox proportional hazard analysis to control for known risk factors. Rapid RRF decline (≥ 0.09 decline) over a 12-month period was associated with a 2.6-fold increase in the risk of death (hazard ratio [HR] 2.60, 95% confidence interval [CI] 1.66 – 4.07, compared with < 0.09 decline) and a 2-fold increase in anuria (HR 2.06, 95% CI 1.24 – 3.42). Each quartile of increasing severity of RRF decline over a 12-month period increased risk incrementally for death (2ndquartile: HR 3.04, CI 1.26 – 7.34; 3rdquartile: HR 4.01, CI 1.71 – 9.83; 4thquartile HR 5.78, CI 2.10 – 15.9) and generally for anuria (quartiles with HR 5.72 – 7.21). The escalating risk of mortality and anuria was greater for those with diabetes mellitus. In conclusion, rapid decline in RRF over a 12-month period increased the risk of mortality and likewise anuria, beyond previously established risk factors for mortality and anuria. The impact on mortality and RRF preservation was particularly severe for those with diabetes mellitus.


2011 ◽  
pp. 30-34
Author(s):  
Hoang Bui Bao Hoang ◽  
Huu Loi Le ◽  
Tam Vo ◽  
Thi Anh Thu Tran

Background: Peritoneal dialysis is used regularlly in treatment of ESRDs. Residual renal function (RRF) in these patients helps the adequacy of PD therapy very much. Objectives: 1. Study RRF of PD patients at Department of Nephro – Rheumatology, Hue Central Hospital. 2. Search the correlation between RRF and Kt/V. Patients and methods: 35 PD patients at Department of Nephro – Rheumatology, Hue Central Hospital. Measure RRF and Kt/V by formulars that depend on blood, urine and PD fluid samples. Results: Mean RRF of PD patients is 4.36 ± 13.8 ml/minute. There is a close correlation between RRF and Kt/V (r=0.79, p<0.01). Conclusion: RRF in PD patients correlates with Kt/V.


2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii264-iii264
Author(s):  
Seung Hyeok Han ◽  
Tae Ik Chang ◽  
Dong-Ryeol Ryu ◽  
Tae-Hyun Yoo ◽  
Hyung Jong Kim ◽  
...  

2020 ◽  
Vol 123 (11) ◽  
pp. 1269-1276
Author(s):  
Steven Law ◽  
Andrew Davenport

AbstractThe majority of peritoneal dialysates use glucose to generate an osmotic gradient for the convective removal of water and Na. Although glucose can potentially be absorbed, previous studies have failed to establish whether this leads to increased fat weight gain. We measured body composition using bioimpedance in peritoneal dialysis (PD) patients, electively starting PD, attending for their first assessment of peritoneal membrane function after 2–3 months, and then after 12 months. We studied 143 patients: eighty-nine (62·2 %) males, fifty-three (37·1 %) diabetics, mean age 61·3 (SD 14·9) years, with ninety (62·1 %) patients treated by automated PD cyclers with a daytime icodextrin exchange and thirty-seven (25·9 %) by continuous ambulatory PD. Median fat mass increased by 1·8 (–0·5 to 4·1) kg, whereas fat-free mass fell –1·3 (–2·9 to 1·0) kg, and the increase in fat mass was negatively associated with the fall in soft lean mass (r –0·41, P < 0·001). Increased fat mass was associated with measured peritoneal glucose absorption (r 0·69, P < 0·001), and glucose absorption was associated with the amount of 22·7 g/l glucose dialysate (OR 2·0, 95 % CI 1·5, 2·5, P < 0·001), peritoneal urea clearance (OR 9·5, 95 % CI 2·4, 37·1, P = 0·001) and male sex (OR 4·8, 95 % CI 1·5, 14·9, P = 0·008). We report an observational study in prevalent PD patients following body composition from their first assessment of PD membrane function for approximately 12 months, and despite the majority of patients prescribed icodextrin, we have demonstrated not only an association between intra-peritoneal glucose absorption and fat weight gain but also loss of fat-free mass.


2019 ◽  
Vol 48 (1) ◽  
pp. 25-31 ◽  
Author(s):  
Sana F. Khan ◽  
Claudio Ronco ◽  
Mitchell H. Rosner

Glucose-based peritoneal dialysis (PD) solutions are the predominantly used dialysate in PD patients. Glucose absorption has been shown to be associated with several unfavorable metabolic complications. Several studies have shown positive effects of exercise in end-stage renal disease patients. This paper provides an overview of glucose-associated metabolic complications, and proposed exercise regimens to counteract the caloric load associated with glucose absorption.


2019 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Andreea Andronesi ◽  
Luminita Iliuta ◽  
Bogdan Obrisca ◽  
Bogdan Sorohan ◽  
Gabriela Lupusoru ◽  
...  

2002 ◽  
Vol 22 (3) ◽  
pp. 415-417 ◽  
Author(s):  
Francisco Caravaca ◽  
Carmen Dominguez ◽  
Manuel Arrobas

2001 ◽  
Vol 21 (3_suppl) ◽  
pp. 152-156 ◽  
Author(s):  
Abelardo Aguilera ◽  
Rosa Codoceo ◽  
M. Auxiliadora Bajo ◽  
Juan J. Diéz ◽  
Gloria Del Peso ◽  
...  

♦ Objective Helicobacter pylori (HP) infection has frequently been found in dialysis patients. Chronic infections induce overproduction of pro-inflammatory substances. Inflammation has been associated with cachexia and anorexia. We explored the relationship between HP infection, anorexia, and malnutrition in peritoneal dialysis (PD) patients. ♦ Patients and Methods The study included 48 clinically stable PD patients divided into four groups: HP+ with anorexia (group I, n = 12); HP+ without anorexia (group II, n = 4); HP- with anorexia (group III, n = 5); and HP- without anorexia (group IV, n = 27). Infection with HP was diagnosed by breath test. Anorexia was evaluated using a personal interview and an eating motivation scale (VAS). The VAS included five questions that are answered before and after eating. The questions concern desire to eat, hunger, feeling of fullness, prospective consumption, and palatability. Biochemical markers of nutrition and inflammation were also determined. ♦ Results At baseline, group I showed lower scores for desire to eat, hunger sensation, prospective consumption, and palatability. They also showed lower lymphocyte counts, prealbumin, transferrin, serum albumin, normalized equivalent of protein–nitrogen appearance (nPNA), and residual renal function (RRF). In addition, the same group showed higher levels of C-reactive protein (CRP) and more sensation of fullness than the remaining groups. In the entire series, we found significant linear correlations between the following markers of nutrition and certain questions on the VAS: albumin with before-lunch desire to eat ( r = 0.38, p < 0.05), and prealbumin with before-lunch hunger ( r = 0.41, p < 0.05) and after-lunch hunger ( r = -0.35, p < 0.05). Negative linear correlations were found between albumin and fullness before lunch ( r = -0.45, p < 0.01), and between prealbumin and before-lunch desire to eat ( r = -0.39, p < 0.05). Negative linear correlations were also seen between CRP and albumin ( r = -0.35, p < 0.05) and between CRP and prealbumin ( r = -0.36, p < 0.05). Similarly, CRP showed a negative correlation with before-lunch desire to eat ( r = -0.38, p < 0.05) and after-lunch desire to eat ( r = -0.45, p < 0.01). After HP eradication, group I showed a significant increase in markers of nutrition and in VAS scores for almost all questions. Simultaneously, they showed a decrease in CRP level. Significant differences were also found in lymphocyte count (1105 ± 259.4 cells/mm3 vs 1330.8 ± 316 cells/mm3, p < 0.05), nPNA (0.9 ± 0.16 g/kg/day vs 1.07 ± 0.3 g/kg/day, p < 0.05), prealbumin (26.7 ± 6.5 mg/dL vs 33.9 ± 56.6 mg/dL, p < 0.01), albumin (3.48 ± 0.3 g/dL vs 3.67 ± 0.35 g/dL, p < 0.05), CRP (1.16 ± 1.14 mg/dL vs 0.88 ± 1.2 mg/dL, p < 0.054), before-lunch desire to eat (56.6 ± 6.8 vs 72.2 ± 4, p < 0.001), after-lunch desire to eat (5.4 ± 2.6 vs 12.3 ± 2, p < 0.01), hunger before lunch (55.4 ± 5.4 vs 73.1 ± 4.6, p < 0.001), hunger after lunch (5.8 ± 2.9 vs 11 ± 4, p < 0.01), fullness before lunch (36.6 ± 10.3 vs 18.7 ± 8.8, p < 0.001), consumption after lunch (5 ± 4.7 vs 17.5 ± 18, p < 0.05), and palatability (61 ± 5.3 vs 74.1 ± 4.1, p < 0.001). ♦ Conclusion Infection with HP is associated with anorexia, inflammation, and malnutrition in PD patients. Eradication of HP significantly improves this syndrome. Residual renal function seem to have a protective effect on appetite preservation. The present study supports the hypothesis of the involvement of inflammation in the pathogenesis of malnutrition in PD patients.


Sign in / Sign up

Export Citation Format

Share Document